3 completed, 3 recruiting, 2 terminated. 7 Phase 1, 4 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 7 | Completed 3, Recruiting 3, Terminated 1 |
| Phase 2 | 4 | Recruiting 3, Completed 1 |
| Phase 3 | 1 | Terminated 1 |
Follow KEYTRUDA® (pembrolizumab): new trials by email Literature Review of KEYTRUDA® (pembrolizumab) trials Research Report on KEYTRUDA® (pembrolizumab)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| ABL103 in Combination With Pembrolizumab, With or Without Taxane in Advanced or Metastatic Solid Tumors ABL103, KEYTRUDA® (pembrolizumab), Taxane - Solid Tumors | Phase 1 / Phase 2 | Recruiting | ABL Bio, Inc. | 65 | 2025-08-06 | 2025-09-08 |
| Regorafenib-pembrolizumab vs. TACE/TARE in Intermediate Stage HCC Beyond Up-to-7 Regorafenib in combination with pembrolizumab, Loco-regional therapy - Carcinoma, Hepatocellular | Phase 3 | Terminated | Translational Research in Oncology | 45 | 2023-10-11 | 2026-03-09 |
| A Study of XmAb®662 as Monotherapy or in Combination With Pembrolizumab in Advanced Solid Tumors XmAb662, Keytruda® (pembrolizumab) - Solid Tumors | Phase 1 | Terminated | Xencor, Inc. | 7 | 2023-07-28 | 2024-08-23 |
| Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or Targeted Therapy and/or ICI, for the Treatment of Patients With Advanced Gastrointestinal Cancers, Including Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study) Spevatamig (PT886), Paclitaxel, Gemcitabine - Gastric or Gastroesophageal Junction Adenocarcinoma, Pancreatic Ductal Adenocarcinoma | Phase 1 / Phase 2 | Recruiting | Phanes Therapeutics | 350 | 2023-03-15 | 2026-09-28 |
| Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAb®808 in Combination With Pembrolizumab in Advanced Solid Tumors XmAb®808, Keytruda® (pembrolizumab) - Head and Neck Squamous Cell Carcinoma, Melanoma Excluding Uveal Melanoma | Phase 1 | Completed | Xencor, Inc. | 60 | 2022-12-14 | 2025-08-07 |
| Study of DF9001 in Patients With Advanced Solid Tumors DF9001, KEYTRUDA® (pembrolizumab) - Solid Tumor, Adult | Phase 1 / Phase 2 | Completed | Dragonfly Therapeutics | 24 | 2022-11-15 | 2025-10-29 |
| Highly Selective CDK7 Inhibitor Q901 in Selected Advanced Solid Tumors Q901, KEYTRUDA® (pembrolizumab) - Advanced Cancer, Metastatic Cancer | Phase 1 / Phase 2 | Recruiting | Qurient Co., Ltd. | 130 | 2022-08-30 | 2025-08-17 |
| Phase 1 Trial of LVGN6051 as Single Agent and in Combination With Keytruda (Pembrolizumab) in Advanced or Metastatic Malignancy LVGN6051, KEYTRUDA® (pembrolizumab) - Cancer | Phase 1 | Completed | Lyvgen Biopharma Holdings Limited | 105 | 2019-10-31 | 2026-05-19 |
Carcinoma, Non-Small-Cell Lung (2) · Carcinoma, Renal Cell (2) · Colorectal Neoplasms (2) · Squamous Cell Carcinoma of Head and Neck (2) · Biliary Tract Neoplasms (1) · Carcinoma, Hepatocellular (1) · Carcinoma, Ovarian Epithelial (1) · Carcinoma, Transitional Cell (1) · Neoplasm Metastasis (1) · Neoplasms (1) · Triple Negative Breast Neoplasms (1)
Xencor, Inc. (2) · ABL Bio, Inc. (1) · Dragonfly Therapeutics (1) · Lyvgen Biopharma Holdings Limited (1) · Phanes Therapeutics (1) · Qurient Co., Ltd. (1) · Translational Research in Oncology (1)
United States (8) · South Korea (3) · Australia (1) · Belgium (1) · France (1) · Georgia (1) · Germany (1) · Hong Kong (1) · Italy (1) · Romania (1) · Serbia (1) · Spain (1) · Taiwan (1) · Turkey (Türkiye) (1)
Chet Bohac, MD (1) · Mira Kistler, MD (1) · Peter R Galle, MD (1) · Richard S Finn, MD (1) · Sangmi Lee (1)